Corbus Pharmaceuticals (CRBP)
(Delayed Data from NSDQ)
$43.50 USD
+0.81 (1.90%)
Updated May 29, 2024 04:00 PM ET
After-Market: $43.48 -0.02 (-0.05%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Corbus Pharmaceuticals Holdings, Inc. [CRBP]
Reports for Purchase
Showing records 1 - 20 ( 60 total )
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
An Early-Stage Pipeline with Compelling Scientific Rationale; Reit. Buy and $3 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Can It Compete? Corbus Expands Its Oncology Footprint With CRB-701, a Nectin-4 Targeting ADC
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Corbus Presenting Preclinical Data For CRB-601 During SITC ?22; Reit Buy and $3 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Integrin aab8 has Promising Potential in Tumor immunotherapy and Remains a Key Long-term Driver; Reit. Buy and $3 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Considerations on CRB-601 in Early I/O Pipeline Development
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
I/O Pipeline Pivot, Creates Questions Before Value; Reit. Buy and $3 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Turning Page to Integrin Development, Strategic Opportunities; SLE Top-line Expected 4Q21
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Focusing on Lenabasum Clarity and Evolving Pipeline Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Lenabasum Setback In DM; Focusing Attention on Next Catalysts
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Diversification Can Further Insulate Pipeline Beyond Lenabasum
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Top-line Data From Lenabasum in DM and SLE at Forefront of Focus; Reit Buy and $3 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A